https://www.pharmaradar360.com/article/best-biotech-stocks-to-add-to-your-watchlist-september-10th-d8ab2eff220ca406PharmaRadar360en2026-09-10T16:04:13.000ZBest Biotech Stocks To Add to Your Watchlist - September 10thhttps://www.pharmaradar360.com/article/xocova-offers-new-post-exposure-covid-19-prevention-option-for-adolescents-180741a4ba145920PharmaRadar360en2026-09-10T15:57:58.000ZXOCOVA offers new post-exposure COVID-19 prevention option for adolescentshttps://www.pharmaradar360.com/article/hsil-extends-biotech-index-to-malaysia-s-warrant-market-7d7be353577cf20ePharmaRadar360en2026-09-10T15:26:05.000ZHSIL extends biotech index to Malaysia’s warrant markethttps://www.pharmaradar360.com/article/kala-shankle-on-what-comes-next-for-national-licensure-74efa622bca91473PharmaRadar360en2026-09-10T15:23:58.000ZKala Shankle on What Comes Next for National Licensurehttps://www.pharmaradar360.com/article/minister-agrees-to-review-pharmacy-amendments-to-health-bill-46a2c884d11eb4a4PharmaRadar360en2026-09-10T15:19:58.000ZMinister agrees to review pharmacy amendments to Health Billhttps://www.pharmaradar360.com/article/ai-changes-the-how-not-the-what-ccddb8218dba7492PharmaRadar360en2026-09-10T15:15:19.000ZAI Changes The How, Not The Whathttps://www.pharmaradar360.com/article/roivant-at-citi-summit-cash-rich-biotech-leans-on-three-pillars-60ac4a42be1a796fPharmaRadar360en2026-09-10T14:55:43.000ZRoivant at Citi summit: cash-rich biotech leans on three pillarshttps://www.pharmaradar360.com/article/phase-3-trial-of-experimental-dm1-treatment-fails-to-hit-main-goal-47fea7492ee4aa03PharmaRadar360en2026-09-10T14:55:06.000ZPhase 3 trial of experimental DM1 treatment fails to hit main goalhttps://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-2130c9870ed50f98PharmaRadar360en2026-09-10T14:45:12.000ZUS FDA pauses new enrollment in Biohaven's epilepsy drug trialshttps://www.pharmaradar360.com/article/burning-rock-biotech-limited-reports-earnings-results-for-the-second-quarter-end-fe9932e3452b9015PharmaRadar360en2026-09-10T14:37:54.000ZBurning Rock Biotech Limited Reports Earnings Results for the Second Quarter Ended June 30, 2026https://www.pharmaradar360.com/article/fifth-circuit-judges-press-louisiana-on-standing-as-mifepristone-stays-available-7803e41623ffd424PharmaRadar360en2026-09-10T14:30:35.000ZFifth Circuit Judges Press Louisiana on Standing as Mifepristone Stays Available by Mail with No Ruling Yethttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharmaRadar360en2026-09-10T14:30:03.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831PharmaRadar360en2026-09-10T14:30:03.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharmaRadar360en2026-09-10T14:30:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharmaRadar360en2026-09-10T14:30:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1PharmaRadar360en2026-09-10T14:30:03.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75PharmaRadar360en2026-09-10T14:30:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharmaRadar360en2026-09-10T14:30:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharmaRadar360en2026-09-10T14:30:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86PharmaRadar360en2026-09-10T14:30:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/how-past-endpoints-11-winners-fared-as-the-biotech-industry-rebounded-b43f9ce8182c04f8PharmaRadar360en2026-09-10T14:30:00.000ZHow past Endpoints 11 winners fared as the biotech industry reboundedhttps://www.pharmaradar360.com/article/pharmaceutical-security-market-competitive-landscape-analyzed-across-leading-glo-ae872b3a3ec772bdPharmaRadar360en2026-09-10T14:30:00.000ZPharmaceutical Security Market Competitive Landscape Analyzed Across Leading Global Companieshttps://www.pharmaradar360.com/article/greater-philadelphia-regional-life-sciences-roundup-september-10-2026-a692fddd69a19c9dPharmaRadar360en2026-09-10T14:28:42.000ZGreater Philadelphia – Regional Life Sciences Roundup – September 10, 2026https://www.pharmaradar360.com/article/glenmark-and-south-piedmont-open-2-7-million-pharmaceutical-training-facility-0b4260fbc2643d82PharmaRadar360en2026-09-10T14:18:32.000ZGlenmark and South Piedmont Open $2.7 Million Pharmaceutical Training Facilityhttps://www.pharmaradar360.com/article/fda-cracks-down-on-unsafe-food-banned-products-17cbcad470576ff1PharmaRadar360en2026-09-10T14:14:27.000ZFDA cracks down on unsafe food, banned productshttps://www.pharmaradar360.com/article/stalled-generous-globe-and-guard-initiatives-create-international-pricing-uncert-01e4dff956d74dffPharmaRadar360en2026-09-10T14:13:42.000ZStalled GENEROUS, GLOBE, and GUARD Initiatives Create International Pricing Uncertainty for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/what-health-equity-champions-can-learn-from-pharmaceutical-sales-9d780c13222a1501PharmaRadar360en2026-09-10T13:59:06.000ZWhat Health Equity Champions Can Learn from Pharmaceutical Saleshttps://www.pharmaradar360.com/article/fda-places-partial-hold-on-biohaven-s-ion-channel-drug-f305595bf9c3c703PharmaRadar360en2026-09-10T13:58:00.000ZFDA places partial hold on Biohaven’s ion channel drughttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharmaRadar360en2026-09-10T13:52:44.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/maharashtra-fda-raids-11-food-units-in-thane-seizes-materials-worth-rs-20-48-lak-9f75fd7cc7276ce7PharmaRadar360en2026-09-10T13:47:26.000ZMaharashtra FDA Raids 11 Food Units in Thane, Seizes Materials Worth Rs 20.48 Lakhhttps://www.pharmaradar360.com/article/frazier-life-sciences-nets-1-1b-in-long-running-fund-aimed-at-small-midsize-biot-6cbd4c5bcf9742ebPharmaRadar360en2026-09-10T13:44:14.000ZFrazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechshttps://www.pharmaradar360.com/article/adarx-pharmaceuticals-seeks-ipo-on-strong-collaboration-deal-with-abbvie-pending-5dba419255f531e9PharmaRadar360en2026-09-10T13:41:31.000ZADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX)https://www.pharmaradar360.com/article/fda-expands-bayer-lung-cancer-drug-approval-71178ea7131e5c0aPharmaRadar360en2026-09-10T13:39:34.000ZFDA expands Bayer lung cancer drug approvalhttps://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-b0c70810964568e8PharmaRadar360en2026-09-10T13:33:05.000ZScenic Biotech appoints renowned neurology drug development leader Dr. Judith Walker as Chief Medical Officerhttps://www.pharmaradar360.com/article/samsung-biologics-signs-usd-262-million-manufacturing-agreement-with-european-ph-d2defa9f379bb988PharmaRadar360en2026-09-10T13:32:47.000ZSamsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical companyhttps://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-4ff7c827c11dfc18PharmaRadar360en2026-09-10T13:30:00.000ZIMUNON Enters Cooperative Research and Developmenthttps://www.pharmaradar360.com/article/west-pharmaceutical-services-at-wells-fargo-conference-growth-outlook-lifts-7e95f35a8d9d2806PharmaRadar360en2026-09-10T13:29:00.000ZWest Pharmaceutical Services at Wells Fargo conference: growth outlook liftshttps://www.pharmaradar360.com/article/scynexis-appoints-sanjay-subramanian-cfo-as-biotech-advances-rare-disease-pipeli-7ffff17544555b0fPharmaRadar360en2026-09-10T13:28:31.000ZSCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipelinehttps://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abbPharmaRadar360en2026-09-10T13:27:33.000ZMajor expansion of community mental health support across Englandhttps://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-5a32cb9618b921d8PharmaRadar360en2026-09-10T13:26:47.000ZmRNA cancer vaccines’ biggest barriers to markethttps://www.pharmaradar360.com/article/takeda-s-long-serving-r-d-chief-andy-plump-to-retire-in-wake-of-pipeline-success-59af07bbf36e86fbPharmaRadar360en2026-09-10T13:25:30.000ZTakeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successeshttps://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964PharmaRadar360en2026-09-10T13:25:15.000ZFrazier Life Sciences adds $1.1B to biotech public fund, lifting it to $2.8Bhttps://www.pharmaradar360.com/article/hplc-degasser-upgraded-biotech-fluidics-launches-the-degasi-ng-platform-28b7579689b125bfPharmaRadar360en2026-09-10T13:23:48.000ZHPLC Degasser Upgraded: Biotech Fluidics Launches the DEGASi NG Platformhttps://www.pharmaradar360.com/article/burning-rock-biotech-releases-q2-2026-financial-results-8819331f3d074a9aPharmaRadar360en2026-09-10T13:22:28.000ZBurning Rock Biotech Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/update-starton-therapeutics-to-present-at-medinvest-biotech-pharma-conference-d467c5ff3d6873ebPharmaRadar360en2026-09-10T13:19:11.000ZUPDATE -- Starton Therapeutics to Present at MedInvest Biotech & Pharma Conferencehttps://www.pharmaradar360.com/article/biotech-pre-market-movers-tnon-aeon-surge-coo-cdt-slide-a99c6eadfee151c8PharmaRadar360en2026-09-10T13:17:00.000ZBiotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slidehttps://www.pharmaradar360.com/article/biovie-seeks-fda-meeting-to-plan-phase-3-trial-for-parkinson-s-drug-candidate-4c45ecc8dc428588PharmaRadar360en2026-09-10T13:16:03.000ZBiovie seeks FDA meeting to plan Phase 3 trial for Parkinson’s drug candidatehttps://www.pharmaradar360.com/article/25f1670-gloflon-i-v-catheter-with-injection-valves-wings-20g-1-1-x-33mm-666903112fb8586ePharmaRadar360en2026-09-10T13:12:22.000ZΑνάκληση της παρτίδας 25F1670 του Ιατροτεχνολογικού προϊόντος Gloflon I.V. CATHETER WITH INJECTION VALVES & WINGS 20G 1.1 x 33mmhttps://www.pharmaradar360.com/article/cannara-biotech-secures-58m-credit-facility-with-bmo-and-td-5c15a8e996887473PharmaRadar360en2026-09-10T13:07:15.000ZCannara Biotech secures $58M credit facility with BMO and TDhttps://www.pharmaradar360.com/article/latest-figures-highlight-ongoing-meningitis-b-risk-for-students-d7de382570d1ec44PharmaRadar360en2026-09-10T13:06:45.000ZLatest figures highlight ongoing Meningitis B risk for studentshttps://www.pharmaradar360.com/article/burning-rock-q2-revenue-falls-9-3-to-rmb134-7m-cafe7127e11ce51ePharmaRadar360en2026-09-10T13:04:51.000ZBurning Rock Q2 revenue falls 9.3% to RMB134.7Mhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090PharmaRadar360en2026-09-10T13:00:00.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69PharmaRadar360en2026-09-10T13:00:00.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/no-treatment-is-approved-for-menstrual-migraine-abbvie-s-drug-cut-migraine-days-6a69b46a841b8f13PharmaRadar360en2026-09-10T12:55:00.000ZNo treatment is approved for menstrual migraine. AbbVie’s drug cut migraine days in a trial.https://www.pharmaradar360.com/article/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-me-aa42924a07011e55PharmaRadar360en2026-09-10T12:55:00.000ZAbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migrainehttps://www.pharmaradar360.com/article/pharma-pulse-dhl-s-new-singapore-hub-and-pharma-rethinks-go-to-market-6f1e39d1bd379b78PharmaRadar360en2026-09-10T12:53:51.000ZPharma Pulse: DHL's New Singapore Hub and Pharma Rethinks Go-To Markethttps://www.pharmaradar360.com/article/geovax-provides-nasdaq-listing-update-and-reaffirms-focus-on-advancing-strategic-e2e455613a5a2210PharmaRadar360en2026-09-10T12:37:21.000ZGeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Prioritieshttps://www.pharmaradar360.com/article/unlocking-cell-surface-protein-research-with-site-specific-labelling-4b2c27c5d4f0630dPharmaRadar360en2026-09-10T12:34:43.000ZUnlocking Cell Surface Protein Research with Site-Specific Labellinghttps://www.pharmaradar360.com/article/oncolytics-biotech-reports-preclinical-pelareorep-activity-maintained-with-ras-i-acb108f11ddc1118PharmaRadar360en2026-09-10T12:21:00.000ZOncolytics Biotech Reports Preclinical Pelareorep Activity Maintained with RAS Inhibitionhttps://www.pharmaradar360.com/article/daesang-expands-into-pharmaceutical-grade-amino-acids-7525345f8975eea5PharmaRadar360en2026-09-10T12:15:44.000ZDaesang expands into pharmaceutical-grade amino acidshttps://www.pharmaradar360.com/article/an-experimental-cancer-treatment-combination-reduced-tumor-growth-in-early-tests-915d2ac78c60b6c6PharmaRadar360en2026-09-10T12:15:00.000ZAn experimental cancer treatment combination reduced tumor growth in early testshttps://www.pharmaradar360.com/article/an-investigational-cell-therapy-for-alzheimer-s-and-parkinson-s-will-be-presente-9bd92b46dfeadd3fPharmaRadar360en2026-09-10T12:05:00.000ZAn investigational cell therapy for Alzheimer’s and Parkinson’s will be presented in Korea.https://www.pharmaradar360.com/article/a-look-at-cleanassure-by-freudenberg-medical-1781dee31e7a4af8PharmaRadar360en2026-09-10T12:00:38.000ZA look at CleanAssure by Freudenberg Medicalhttps://www.pharmaradar360.com/article/imn-screws-system-advanced-locking-screw-ec5f499d9db6b051PharmaRadar360en2026-09-10T12:00:00.000ZIMN Screws System Advanced Locking Screwhttps://www.pharmaradar360.com/article/data-on-five-year-remission-with-a-myeloma-treatment-will-be-presented-in-scotla-a31339569a772091PharmaRadar360en2026-09-10T12:00:00.000ZData on five-year remission with a myeloma treatment will be presented in Scotlandhttps://www.pharmaradar360.com/article/why-is-biohaven-pharmaceutical-stock-sliding-today-d8352213f625eea5PharmaRadar360en2026-09-10T11:46:41.000ZWhy is Biohaven Pharmaceutical stock sliding today?https://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8fPharmaRadar360en2026-09-10T11:35:38.000ZData Aggregation Drives AI's Impact on Clinical Supply Chainshttps://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-8e9e18b565ad084ePharmaRadar360en2026-09-10T11:34:16.000ZCervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026https://www.pharmaradar360.com/article/3145507-hippokratis-10x20-ply-ref-1020121301-070cc64470b4812dPharmaRadar360en2026-09-10T11:33:51.000ZΑνάκληση της παρτίδας 3145507 του ιατροτεχνολογικού προϊόντος HIPPOKRATIS Επιθέματα γάζας μη αποστειρωμένα 10X20 PLY, REF: 1020121301https://www.pharmaradar360.com/article/biotech-hair-brand-vegamour-snapped-up-by-kvd-beauty-owner-belle-brands-9e5b5f7223daebe3PharmaRadar360en2026-09-10T11:30:39.000ZBiotech hair brand Vegamour snapped up by KVD Beauty owner Belle Brandshttps://www.pharmaradar360.com/article/burning-rock-biotech-s-q2-revenue-falls-net-loss-widens-on-central-laboratory-we-3a2bfe5a57b7c6c6PharmaRadar360en2026-09-10T11:29:04.000ZBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weaknesshttps://www.pharmaradar360.com/article/burning-rock-biotech-reports-second-quarter-2026-financial-results-and-business-3604b6a838f831f6PharmaRadar360en2026-09-10T11:20:00.000ZBurning Rock Biotech Reports Second Quarter 2026 Financial Results and Business Updateshttps://www.pharmaradar360.com/article/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-appl-173e26866817c76ePharmaRadar360en2026-09-10T11:13:17.000ZPrelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degraderhttps://www.pharmaradar360.com/article/can-simulation-help-foundation-trainee-pharmacists-prepare-for-prescribing-754b389753a9f647PharmaRadar360en2026-09-10T11:12:33.000ZCan simulation help foundation trainee pharmacists prepare for prescribing?https://www.pharmaradar360.com/article/migraine-and-acne-included-in-new-prescribing-pharmacy-first-pathways-3ea2469614a56a9cPharmaRadar360en2026-09-10T11:12:33.000ZMigraine and acne included in new prescribing Pharmacy First pathwayshttps://www.pharmaradar360.com/article/uzbekistan-pharmaceutical-output-reaches-uzs-3-5-trillion-in-seven-months-e698870d82152c1bPharmaRadar360en2026-09-10T11:10:20.000ZUzbekistan Pharmaceutical Output Reaches UZS 3.5 Trillion in Seven Monthshttps://www.pharmaradar360.com/article/phase-1-2-clinical-trial-of-opgx-best1-shows-positive-results-for-inherited-reti-693efb757e3769e0PharmaRadar360en2026-09-10T11:09:11.000ZPhase 1/2 clinical trial of OPGx-BEST1 shows positive results for inherited retinal diseaseshttps://www.pharmaradar360.com/article/podcast-key-readouts-from-esc-and-ers-37928ee094726d75PharmaRadar360en2026-09-10T11:00:34.000ZPodcast: key readouts from ESC and ERShttps://www.pharmaradar360.com/article/new-suicide-risk-research-will-join-five-posters-on-a-treatment-e30968146e5d4bbaPharmaRadar360en2026-09-10T11:00:00.000ZNew suicide-risk research will join five posters on a treatmenthttps://www.pharmaradar360.com/article/sk-biopharm-s-in-licensed-epilepsy-drug-opcalim-hits-partial-fda-clinical-hold-58e7c243c85a1a2cPharmaRadar360en2026-09-10T10:55:00.000ZSK Biopharm's In-Licensed Epilepsy Drug OPCALIM Hits Partial FDA Clinical Holdhttps://www.pharmaradar360.com/article/hhs-appoints-permanent-fda-cber-cder-heads-40d9e998d4d06de3PharmaRadar360en2026-09-10T10:52:30.000ZHHS appoints permanent FDA CBER, CDER headshttps://www.pharmaradar360.com/article/spain-pushes-for-access-toolbox-in-eu-biotech-rules-1688a317e36915f9PharmaRadar360en2026-09-10T10:48:05.000ZSpain pushes for ‘access toolbox’ in EU biotech ruleshttps://www.pharmaradar360.com/article/join-the-danish-medicines-agency-s-atmp-open-house-c8681c32f51f75b3PharmaRadar360en2026-09-10T10:39:00.000ZJoin the Danish Medicines Agency’s ATMP Open Househttps://www.pharmaradar360.com/article/what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout-e0aa083eeef3c734PharmaRadar360en2026-09-10T10:36:24.000ZWhat to expect from UniQure’s upcoming Huntington’s gene therapy readouthttps://www.pharmaradar360.com/article/roivant-is-one-of-the-savviest-dealmakers-in-biotech-it-also-has-a-secret-weapon-c406bfe29c9a43b3PharmaRadar360en2026-09-10T10:36:24.000ZRoivant is one of the savviest dealmakers in biotech. It also has a secret weaponhttps://www.pharmaradar360.com/article/squarepoint-ops-llc-sells-106-171-shares-of-ultragenyx-pharmaceutical-inc-rare-aaef604b00280d03PharmaRadar360en2026-09-10T10:16:39.000ZSquarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RAREhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-prices-4-9-billion-senior-notes-offering-and-anno-b1e8ff5e4e7ab9dfPharmaRadar360en2026-09-10T10:11:00.000ZTeva Pharmaceutical Industries Prices $4.9 Billion Senior Notes Offering and Announces Conditional Redemptionshttps://www.pharmaradar360.com/article/power-optimization-solution-ends-costly-grid-related-shutdowns-at-major-pharmace-895389c9339efb13PharmaRadar360en2026-09-10T10:00:00.000ZPower Optimization Solution Ends Costly Grid-Related Shutdowns at Major Pharmaceutical Manufacturing Planthttps://www.pharmaradar360.com/article/active-pharmaceutical-ingredients-market-demand-insights-ee7be79d74ee8b32PharmaRadar360en2026-09-10T09:46:00.000ZActive Pharmaceutical Ingredients Market Demand Insightshttps://www.pharmaradar360.com/article/one-assessment-27-countries-how-eu-joint-reviews-work-afdce1a4bab2fa1aPharmaRadar360en2026-09-10T09:44:09.000ZOne assessment, 27 countries: how EU joint reviews workhttps://www.pharmaradar360.com/article/when-the-er-is-not-an-option-milestone-s-cmo-on-bringing-afib-rate-control-home-e2e99f9bbe1ee809PharmaRadar360en2026-09-10T09:36:31.000ZWhen the ER Is Not an Option: Milestone’s CMO on Bringing AFib Rate Control Homehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-takeda-announces-planned-retirement-of-president-of-cc51e8d4bc8214ffPharmaRadar360en2026-09-10T09:34:28.000ZTakeda Pharmaceutical Co Ltd - Takeda Announces Planned Retirement Of President Of Research & Development Andy Plump Effective June 2027https://www.pharmaradar360.com/article/takeda-pharmaceutical-announces-planned-retirement-of-president-of-research-deve-57aa87713cda8888PharmaRadar360en2026-09-10T09:34:06.000ZTakeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plumphttps://www.pharmaradar360.com/article/systech-launches-traceiq-0628e750134c6813PharmaRadar360en2026-09-10T09:33:40.000ZSystech launches TraceIQhttps://www.pharmaradar360.com/article/how-ud-s-star-campus-is-helping-companies-foster-innovation-in-biotech-bfd0e22feb57c6cbPharmaRadar360en2026-09-10T09:31:00.000ZHow UD's STAR Campus is helping companies foster innovation in biotechhttps://www.pharmaradar360.com/article/biotech-growth-trust-stands-out-in-a-stronger-biotechnology-sector-0c5fc1ee6f1de77bPharmaRadar360en2026-09-10T09:24:00.000ZBiotech Growth Trust Stands Out In A Stronger Biotechnology Sectorhttps://www.pharmaradar360.com/article/me-therapeutics-stock-faces-downside-pressure-as-biotech-risk-and-preclinical-un-1ec2178796d0ffa0PharmaRadar360en2026-09-10T09:19:00.000ZME Therapeutics Stock Faces Downside Pressure as Biotech Risk and Preclinical Uncertainty Weigh on Sentimenthttps://www.pharmaradar360.com/article/biocorrx-inc-appoints-former-acting-white-house-drug-policy-director-richard-j-b-f65963320838259aPharmaRadar360en2026-09-10T09:16:00.000ZBioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Boardhttps://www.pharmaradar360.com/article/yourgene-insight-dpyd-assay-gets-ivdr-accreditation-0f45b3e7e51c89f2PharmaRadar360en2026-09-10T09:10:10.000ZYourgene Insight DPYD assay gets IVDR accreditationhttps://www.pharmaradar360.com/article/mog-fda-35ed387f5c4715cePharmaRadar360en2026-09-10T09:00:00.000Zエンスプリングに関するロシュ社の発表について（MOG抗体関連疾患に対するFDAによる申請受理および優先審査指定）https://www.pharmaradar360.com/article/roche-announces-u-s-fda-grants-priority-review-for-enspryng-for-myelin-oligodend-399e802924ad2be2PharmaRadar360en2026-09-10T09:00:00.000ZRoche Announces U.S. FDA Grants Priority Review for Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)https://www.pharmaradar360.com/article/samsung-biologics-signs-350-8-billion-long-term-cmo-deal-with-european-pharmaceu-f69633ea36eaf3adPharmaRadar360en2026-09-10T08:55:00.000ZSamsung Biologics Signs ₩350.8 Billion Long-Term CMO Deal with European Pharmaceutical Companyhttps://www.pharmaradar360.com/article/biotech-fluidics-launch-degasi-ng-platform-03359e408ef2f244PharmaRadar360en2026-09-10T08:47:40.000ZBiotech Fluidics launch DEGASi NG platformhttps://www.pharmaradar360.com/article/dong-a-socio-holdings-to-rename-itself-dong-a-pharmaceutical-after-otc-merger-811dc3505dca9b48PharmaRadar360en2026-09-10T08:46:07.000ZDong-A Socio Holdings to rename itself Dong-A Pharmaceutical after OTC mergerhttps://www.pharmaradar360.com/article/biotech-fluidics-upgrades-its-degasi-inline-degasser-range-2e8eb202eff2dd75PharmaRadar360en2026-09-10T08:35:23.000ZBiotech Fluidics upgrades its Degasi inline degasser rangehttps://www.pharmaradar360.com/article/why-evidence-matters-seema-meloni-on-making-data-meaningful-ec1cdcab294170daPharmaRadar360en2026-09-10T08:33:17.000ZWhy evidence matters: Seema Meloni on making data meaningfulhttps://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323PharmaRadar360en2026-09-10T08:30:10.000ZSalmonella outbreak updatehttps://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884PharmaRadar360en2026-09-10T08:30:07.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007PharmaRadar360en2026-09-10T08:30:05.000ZSalmonella statistical releaseshttps://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60PharmaRadar360en2026-09-10T08:30:04.000ZMeningococcal disease: laboratory-confirmed cases in England 2025 to 2026https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20cePharmaRadar360en2026-09-10T08:30:03.000ZAntimicrobial resistance awareness: toolkit for healthcare providershttps://www.pharmaradar360.com/article/venture-investor-danish-biotech-innovation-has-caught-up-with-sweden-3b75feb145abd779PharmaRadar360en2026-09-10T08:20:45.000ZVenture investor: Danish biotech innovation has caught up with Swedenhttps://www.pharmaradar360.com/article/pharmaceutical-packaging-market-c2e9bc2e819d9a7bPharmaRadar360en2026-09-10T08:16:48.000ZPharmaceutical Packaging Markethttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-22eadb56d9fb8544PharmaRadar360en2026-09-10T08:16:08.000ZEbola disease caused by Bundibugyo virus - Democratic Republic of the Congohttps://www.pharmaradar360.com/article/gov-healey-eyes-changes-to-life-sciences-programs-as-early-stage-biotechs-strugg-17782bbe9a7546e8PharmaRadar360en2026-09-10T08:00:00.000ZGov. Healey eyes changes to life sciences programs as early-stage biotechs strugglehttps://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-e6c409ade4de9fa6PharmaRadar360en2026-09-10T07:51:03.000ZScenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officerhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-6-september-2026-10a6be24e936e540PharmaRadar360en2026-09-10T07:34:29.000ZWeekly all-cause mortality surveillance: week ending 6 September 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-820ecbff0a7a966cPharmaRadar360en2026-09-10T07:29:12.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to April to June 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-335870a76488db42PharmaRadar360en2026-09-10T07:28:52.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to January to March 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-ae1ac0815b2896b3PharmaRadar360en2026-09-10T07:27:39.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to October to December 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-bfc75e0710215140PharmaRadar360en2026-09-10T07:26:59.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to July to September 2026https://www.pharmaradar360.com/article/hhs-names-permanent-leaders-of-fda-drug-and-vaccine-centers-setting-the-directio-a1123af1f2b72c44PharmaRadar360en2026-09-10T07:19:45.000ZHHS Names Permanent Leaders of FDA Drug and Vaccine Centers, Setting the Direction for Future Reviewshttps://www.pharmaradar360.com/article/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approve-0b079b33cbbfd08dPharmaRadar360en2026-09-10T07:00:55.000ZGSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japanhttps://www.pharmaradar360.com/article/insilico-medicine-begins-phase-iii-trial-of-ai-discovered-drug-rentosertib-for-i-dadb1e5c66814ac8PharmaRadar360en2026-09-10T06:46:29.000ZInsilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPFhttps://www.pharmaradar360.com/article/psi-cro-to-present-agile-models-for-emerging-biotech-at-oct-new-england-833dc325de531768PharmaRadar360en2026-09-10T06:46:29.000ZPSI CRO to Present Agile Models for Emerging Biotech at OCT New Englandhttps://www.pharmaradar360.com/article/seismic-pharmaceuticals-enrolls-first-patient-in-phase-3-trial-of-istaroxime-for-2b1bb847cd17d245PharmaRadar360en2026-09-10T06:46:29.000ZSeismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shockhttps://www.pharmaradar360.com/article/genencell-scandal-revives-korea-s-kosdaq-bio-rout-as-trust-erodes-and-risk-mount-fb54093710b5acb6PharmaRadar360en2026-09-10T06:31:00.000ZGenencell scandal revives Korea’s KOSDAQ bio rout as trust erodes and risk mounts - CHOSUNBIZhttps://www.pharmaradar360.com/article/chinese-salmon-by-products-targeted-in-12-8m-biotech-deal-c8108b005d948e22PharmaRadar360en2026-09-10T05:04:03.000ZChinese salmon by-products targeted in €12.8m biotech dealhttps://www.pharmaradar360.com/article/u-s-fda-grants-priority-review-for-roche-s-enspryng-for-mogad-an-autoimmune-dise-74fecb34511c53e2PharmaRadar360en2026-09-10T05:00:00.000ZU.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatmentshttps://www.pharmaradar360.com/article/stavros-nicolaou-represents-aspen-at-the-9th-annual-sadc-industrialisation-week-07118bf02b625030PharmaRadar360en2026-09-10T05:00:00.000ZStavros Nicolaou represents Aspen at the 9th Annual SADC Industrialisation Weekhttps://www.pharmaradar360.com/article/finnish-aq-biotech-raises-2-5m-to-scale-cancer-screening-in-china-4d00cc33ac6dddf2PharmaRadar360en2026-09-10T04:29:20.000ZFinnish AQ Biotech raises €2.5M to scale cancer screening in Chinahttps://www.pharmaradar360.com/article/harbour-biomed-advances-long-acting-antibody-candidate-to-phase-3-trial-bb7175ea04a5f45ePharmaRadar360en2026-09-10T03:42:59.000ZHarbour BioMed advances long-acting antibody candidate to Phase 3 trialhttps://www.pharmaradar360.com/article/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results-1881334f1adeeee7PharmaRadar360en2026-09-10T03:34:57.000ZKelun-Biotech partner reports positive asthma Phase 2 trial resultshttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-remede-system-7f6e3ec0b271b2e3PharmaRadar360en2026-09-10T03:00:00.000Z[SHINSA]English Translation of Review Report: remedē Systemhttps://www.pharmaradar360.com/article/kenanga-investment-bank-introduces-world-s-first-hang-seng-biotech-index-structu-2d2c97ee8f163699PharmaRadar360en2026-09-10T02:54:34.000ZKenanga Investment Bank Introduces World’s First Hang Seng Biotech Index Structured Warrants to Malaysiahttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-10T02:49:40.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/nanjing-zhongchun-biotech-rooted-in-the-ancient-capital-a-reliable-partner-in-fi-f233ef0f32fa8f8aPharmaRadar360en2026-09-10T02:36:29.000ZNanjing Zhongchun Biotech: Rooted in the Ancient Capital, a Reliable Partner in Fine Chemicalshttps://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-d26bebab03c30cc8PharmaRadar360en2026-09-10T02:23:35.000ZACES Alumna Employs Biotech to Create Sustainable Livestock Productionhttps://www.pharmaradar360.com/article/insilico-medicine-doses-first-patient-in-genesis-ipf-3-the-world-s-first-phase-i-e40660aaa25393abPharmaRadar360en2026-09-10T00:30:00.000ZInsilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drughttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-9f35af525cd09cc9PharmaRadar360en2026-09-10T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-29706f5bf24237ffPharmaRadar360en2026-09-10T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-5e0d92994d60f5a4PharmaRadar360en2026-09-10T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-d81b0bf746dea1d5PharmaRadar360en2026-09-10T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-bed409cbf5ace142PharmaRadar360en2026-09-10T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-0a8fecb54a3fc423PharmaRadar360en2026-09-10T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-8ecf642e68d895e2PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-1f9381361a06f286PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-fbc5f4932d6017a5PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-9b2cd91149447d39PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-099ad11c1b7cf6fdPharmaRadar360en2026-09-10T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-af717744324c797aPharmaRadar360en2026-09-10T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-55971ce00f6a5b47PharmaRadar360en2026-09-10T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-7c0c91083a2a7674PharmaRadar360en2026-09-10T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-0da438f85c422491PharmaRadar360en2026-09-10T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/green-innovation-gmbh-withdrawal-of-food-additive-petition-animal-use-d90074417ad7c799PharmaRadar360en2026-09-10T00:00:00.000ZGreen Innovation GmbH; Withdrawal of Food Additive Petition (Animal Use)https://www.pharmaradar360.com/article/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2027-091f27d76fcd85b3PharmaRadar360en2026-09-10T00:00:00.000ZFee Rate for Using a Priority Review Voucher in Fiscal Year 2027https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-2abdf53dea0a6290PharmaRadar360en2026-09-10T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-public-online-rou-60eabdf6f3844b70PharmaRadar360en2026-09-10T00:00:00.000ZNational Center for Advancing Translational Sciences; Notice of Public Online Roundtablehttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-mechanical-deviatio-e4a18073cc69ba43PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Mechanical Deviation Device for Esophageal Protection During Cardiac Ablation Procedureshttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-temperature-regulat-1550b33975ad5831PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Temperature Regulation Device for Esophageal Protection During Cardiac Ablation Procedureshttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-extravascular-suppo-cc4f76058ba83528PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Extravascular Support for an Arteriovenous Fistula for Vascular Accesshttps://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classificatio-95c9753661159e4cPharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody Test System for Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/medical-devices-ear-nose-and-throat-devices-classification-of-the-cooperative-po-053f86715c0fa357PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Ear, Nose, and Throat Devices; Classification of the Cooperative Powered Surgical Assist Device for ENT Surgeryhttps://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-implanted-19651965512a4fdcPharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Gastroenterology-Urology Devices; Classification of the Implanted Tibial Electrical Urinary Continence Devicehttps://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-vaginal-hydrogel-packing-cf0bb5f7ee0efe46PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Radiology Devices; Classification of the Vaginal Hydrogel Packing Systemhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-e53ed8cdd83debacPharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Whole Room Microbial Reduction Devicehttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-bc670a4d8a9047aaPharmaRadar360en2026-09-10T00:00:00.000ZNotice of Supplemental Funding, Medicare Rural Hospital Flexibility Programhttps://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-to-the-senior-medicare-1c16ee7d1b83e6c7PharmaRadar360en2026-09-10T00:00:00.000ZAnnouncing the Intent To Award a Single-Source Supplement to the Senior Medicare Patrol (SMP) Resource Centerhttps://www.pharmaradar360.com/article/a-retrospective-analysis-of-clinical-outcomes-following-human-deviations-from-al-60989f4665caf7cePharmaRadar360en2026-09-10T00:00:00.000ZA Retrospective Analysis of Clinical Outcomes Following Human Deviations from Algorithmic Recommendationshttps://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3PharmaRadar360en2026-09-10T00:00:00.000ZShort-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-function-of-angiotensin-converting-enzyme-inhibitors-in-chronic-kidney-disea-8f6ef8fb6d240f67PharmaRadar360en2026-09-10T00:00:00.000ZThe Function of Angiotensin-Converting Enzyme Inhibitors in Chronic Kidney Disease: Pathophysiological Mechanisms and Implications for Practicehttps://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5PharmaRadar360en2026-09-10T00:00:00.000ZProposals for Individually Safe and Realistic Correction of Antipsychotics in Hospitalized Patients with Schizophrenia: A Prescription Survey at Nagoya University Hospitalhttps://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9PharmaRadar360en2026-09-10T00:00:00.000ZDevelopment of a Rubric for Assessing Essential “Basic Social Skills” Required at the Time of Employment and Its Evaluation in Clinical Traininghttps://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252PharmaRadar360en2026-09-10T00:00:00.000ZClinical Evaluation of Reduced-Dose versus Standard-Dose Remdesivir in Patients with eGFR &lt; 30 mL/min/1.73m&lt;sup&gt;2&lt;/sup&gt;: Effectiveness and Safetyhttps://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4PharmaRadar360en2026-09-10T00:00:00.000ZCharacteristics of Medication Errors Prevented by Community Pharmacists During Transition of Carehttps://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49PharmaRadar360en2026-09-10T00:00:00.000ZPharmacist Secondment, Implementation of Ward-based Pharmaceutical Services, and Challenges in Medication Information Sharing during Care Transitionshttps://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026cPharmaRadar360en2026-09-10T00:00:00.000ZContinuous Intervention by an Antimicrobial Stewardship Pharmacist Contributes to Successful Treatment of a Brain Abscess: A Case Reporthttps://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7aPharmaRadar360en2026-09-10T00:00:00.000ZIdentification of Risk Factors for Lithium-Associated Renal Impairment: A Multicenter Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082PharmaRadar360en2026-09-10T00:00:00.000ZEvaluation of Treatment Continuation and Tolerability Using the Urine Protein-to-Creatinine Ratio (UPC Ratio) as a Criterion for Proteinuria in Patients with Colorectal Cancer Receiving Bevacizumabhttps://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3bPharmaRadar360en2026-09-10T00:00:00.000ZImplementation of the Electronic Tracing Report System and Evaluation of its Usefulnesshttps://www.pharmaradar360.com/article/introduction-fcc82029050d3cfcPharmaRadar360en2026-09-10T00:00:00.000ZIntroductionhttps://www.pharmaradar360.com/article/epidemiology-of-acute-kidney-injury-aki-and-sepsis-associated-aki-in-critically-b6d5977523dd237cPharmaRadar360en2026-09-10T00:00:00.000ZEpidemiology of acute kidney injury (AKI) and sepsis-associated AKI in critically ill patients: A retrospective cohort studyhttps://www.pharmaradar360.com/article/the-effect-of-a-telephonic-reminder-on-fasting-duration-in-children-undergoing-c-81dd7d56c74043e5PharmaRadar360en2026-09-10T00:00:00.000ZThe effect of a telephonic reminder on fasting duration in children undergoing computed tomography scan under sedation in a resource-limited setting – A randomized controlled trialhttps://www.pharmaradar360.com/article/comparative-evaluation-of-sternomental-and-hyomental-distance-based-dynamic-airw-9b0a21c89b21e9a8PharmaRadar360en2026-09-10T00:00:00.000ZComparative evaluation of sternomental and hyomental distance–based dynamic airway indices for predicting difficult laryngoscopy in obese surgical patients: A prospective observational studyhttps://www.pharmaradar360.com/article/phantom-plethysmography-a-pulse-oximeter-artifact-caused-by-ambient-light-9d789979f52ddb2dPharmaRadar360en2026-09-10T00:00:00.000ZPhantom plethysmography: A pulse oximeter artifact caused by ambient lighthttps://www.pharmaradar360.com/article/thoracic-continuous-spinal-anesthesia-for-prolonged-thoracolumbar-fixation-and-k-39160d2fd342c76ePharmaRadar360en2026-09-10T00:00:00.000ZThoracic continuous spinal anesthesia for prolonged thoracolumbar fixation and kyphoplasty in a high-risk geriatric patient with severe pulmonary comorbidityhttps://www.pharmaradar360.com/article/morphine-ketamine-combination-for-acute-trauma-analgesia-unanswered-questions-be-a688b64ea7fdcefbPharmaRadar360en2026-09-10T00:00:00.000ZMorphine–ketamine combination for acute trauma analgesia: Unanswered questions beyond the meta-analysishttps://www.pharmaradar360.com/article/therapeutic-responses-and-6-month-clinical-outcomes-in-sarcoidosis-a-longitudina-1dfb2b94343d3422PharmaRadar360en2026-09-10T00:00:00.000ZTherapeutic Responses and 6-month Clinical Outcomes in Sarcoidosis: A Longitudinal Study in a Tertiary South Indian Cohorthttps://www.pharmaradar360.com/article/comparative-evaluation-of-patient-performed-cleaning-methods-on-the-integrity-of-1841900d0724de48PharmaRadar360en2026-09-10T00:00:00.000ZComparative Evaluation of Patient-Performed Cleaning Methods on the Integrity of Clear Orthodontic Aligners: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/clinical-profile-risk-factors-and-treatment-outcomes-of-diabetic-foot-ulcers-a-p-4373b3d863bde44dPharmaRadar360en2026-09-10T00:00:00.000ZClinical Profile, Risk Factors and Treatment Outcomes of Diabetic Foot Ulcers: A Prospective Observational Study from a Tertiary Care Teaching Hospitalhttps://www.pharmaradar360.com/article/association-between-brain-natriuretic-peptide-and-intradialytic-hypotension-in-h-a365fbb4949ebe9dPharmaRadar360en2026-09-10T00:00:00.000ZAssociation Between Brain Natriuretic Peptide and Intradialytic Hypotension in Hemodialysis Patients: A Retrospective Studyhttps://www.pharmaradar360.com/article/left-atrial-appendage-occlusion-vs-oral-anticoagulants-current-evidence-and-deba-5f809c5eb8e4f23bPharmaRadar360en2026-09-10T00:00:00.000ZLeft Atrial Appendage Occlusion vs. Oral Anticoagulants: Current Evidence and Debateshttps://www.pharmaradar360.com/article/electrotherapy-in-pediatric-rehabilitation-a-structured-narrative-review-of-clin-d2236a91b304d8e6PharmaRadar360en2026-09-10T00:00:00.000ZElectrotherapy in Pediatric Rehabilitation: A Structured Narrative Review of Clinical Applications, Treatment Parameters, Safety, and Evidence Gapshttps://www.pharmaradar360.com/article/cbct-based-anatomical-assessment-of-lingual-bone-availability-relevant-to-the-me-4d89c9009e1b662aPharmaRadar360en2026-09-10T00:00:00.000ZCBCT-Based Anatomical Assessment of Lingual Bone Availability Relevant to the Mental Foramen Bypass Concept in Posterior Atrophied Mandibleshttps://www.pharmaradar360.com/article/personality-and-coming-to-terms-with-cancer-a-cross-sectional-study-of-five-fact-0ead1686b1643e4bPharmaRadar360en2026-09-10T00:00:00.000ZPersonality and Coming to Terms with Cancer: A Cross-Sectional Study of Five-Factor Traits and Illness Acceptance in Oncology Outpatientshttps://www.pharmaradar360.com/article/circulating-interleukin-17-across-airway-disease-phenotypes-a-single-center-obse-2fdf11ea2437bca3PharmaRadar360en2026-09-10T00:00:00.000ZCirculating Interleukin-17 Across Airway Disease Phenotypes: A Single-Center Observational Studyhttps://www.pharmaradar360.com/article/impact-of-age-on-success-of-3d-printed-cranial-remolding-orthoses-for-deformatio-9aa46e3dc891e64dPharmaRadar360en2026-09-10T00:00:00.000ZImpact of Age on Success of 3D-Printed Cranial Remolding Orthoses for Deformational Head Shapeshttps://www.pharmaradar360.com/article/exercise-induced-bronchoconstriction-in-school-aged-children-born-very-preterm-p-ae54f67e30689774PharmaRadar360en2026-09-10T00:00:00.000ZExercise-Induced Bronchoconstriction in School-Aged Children Born Very Preterm: Prevalence and Associated Clinical Factorshttps://www.pharmaradar360.com/article/multilevel-mechanisms-and-clinical-efficacy-of-psilocybin-in-depression-treatmen-c152eb701a32b92cPharmaRadar360en2026-09-10T00:00:00.000ZMultilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Reviewhttps://www.pharmaradar360.com/article/user-centered-design-approach-to-dynamic-clinical-decision-support-in-primary-pr-311b856abb73970dPharmaRadar360en2026-09-10T00:00:00.000ZUser-Centered Design Approach to Dynamic Clinical Decision Support in Primary Prevention of Cardiovascular Diseasehttps://www.pharmaradar360.com/article/comment-on-huang-et-al-accuracy-and-agreement-of-a-45-mg-versus-a-75-mg-13c-urea-c3adf5d3af9f3d93PharmaRadar360en2026-09-10T00:00:00.000ZComment on Huang et al. Accuracy and Agreement of a 45 mg Versus a 75 mg 13C-Urea Breath Test for the Diagnosis of Helicobacter pylori Infection in Adults: A Randomized Crossover Trial. Diagnostics 2026, 16, 1567https://www.pharmaradar360.com/article/clinical-outcomes-and-new-treatments-in-pediatric-brain-tumors-a7ae81bda7df0329PharmaRadar360en2026-09-10T00:00:00.000ZClinical Outcomes and New Treatments in Pediatric Brain Tumorshttps://www.pharmaradar360.com/article/from-mitochondrial-support-to-mitohormetic-readiness-a-micronutrient-centric-ext-f324d9fbecf27cf9PharmaRadar360en2026-09-10T00:00:00.000ZFrom Mitochondrial Support to Mitohormetic Readiness: A Micronutrient-Centric Extension of the Energy Allocation Systemhttps://www.pharmaradar360.com/article/impact-of-ethanol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-patients-w-272a8ec4a97d9120PharmaRadar360en2026-09-10T00:00:00.000ZImpact of ethanol sclerotherapy on pelvic pain and quality of life in patients with endometriomas (ESCOMA study): protocol for a randomised clinical trialhttps://www.pharmaradar360.com/article/comparison-of-live-birth-rates-between-calorie-restricted-diet-and-metformin-pri-e6f52d6cd1926e2dPharmaRadar360en2026-09-10T00:00:00.000ZComparison of live birth rates between calorie-restricted diet and metformin prior to ovulation induction therapy in women with polycystic ovary syndrome and overweight/obesity: a protocol for a multicenter, randomized comparative effectiveness trialhttps://www.pharmaradar360.com/article/shunt-pathophysiological-mechanisms-and-clinical-implications-of-ineffective-cir-3955f02cf56865e4PharmaRadar360en2026-09-10T00:00:00.000ZShunt: pathophysiological mechanisms and clinical implications of ineffective circulating volumehttps://www.pharmaradar360.com/article/hypericin-and-hyperforin-from-st-john-s-wort-are-potent-intestinal-ugt-inhibitor-10d289e1efb49df5PharmaRadar360en2026-09-10T00:00:00.000ZHypericin and hyperforin from St. John’s Wort are potent intestinal UGT inhibitors with distinct binding modes: mechanistic and quantitative prediction of clinical drug–drug interaction riskhttps://www.pharmaradar360.com/article/foxc1-drives-lung-cancer-metastasis-and-functions-as-a-target-for-ai-enabled-ant-1defa9cda85e5e4fPharmaRadar360en2026-09-10T00:00:00.000ZFOXC1 drives lung cancer metastasis and functions as a target for AI-enabled anti-metastatic drug discoveryhttps://www.pharmaradar360.com/article/beyond-a-negative-trial-timing-molecular-residual-disease-and-antibody-biology-i-bb05374d7dd1fb5ePharmaRadar360en2026-09-10T00:00:00.000ZBeyond a negative trial: timing, molecular residual disease, and antibody biology in adjuvant immunotherapy for resected NSCLChttps://www.pharmaradar360.com/article/acupuncture-for-chronic-tinnitus-study-protocol-for-a-clinical-trial-with-audito-8863c954452a2b82PharmaRadar360en2026-09-10T00:00:00.000ZAcupuncture for chronic tinnitus: study protocol for a clinical trial with auditory brainstem response outcomeshttps://www.pharmaradar360.com/article/control-effect-of-dual-mechanism-myopia-control-lenses-on-myopia-in-children-and-7da4cb5525ea95aaPharmaRadar360en2026-09-10T00:00:00.000ZControl effect of dual-mechanism myopia control lenses on myopia in children and adolescents: a prospective, 12-month, non-randomized, parallel-controlled, and single-center trial protocolhttps://www.pharmaradar360.com/article/clinical-warrant-in-medical-llm-evaluation-459f9d52d16df761PharmaRadar360en2026-09-10T00:00:00.000ZClinical warrant in medical LLM evaluationhttps://www.pharmaradar360.com/article/presidential-inaugural-address-2026-expanding-computer-based-testing-strengtheni-15fe341fe4ecbd79PharmaRadar360en2026-09-10T00:00:00.000ZPresidential inaugural address 2026: expanding computer-based testing, strengthening clinical competency assessment, and adopting artificial intelligence with caution in health professions licensing examinations in Koreahttps://www.pharmaradar360.com/article/artificial-intelligence-and-the-right-to-a-fair-trial-in-the-context-of-ensuring-b0afc141737b48adPharmaRadar360en2026-09-10T00:00:00.000ZARTIFICIAL INTELLIGENCE AND THE RIGHT TO A FAIR TRIAL IN THE CONTEXT OF ENSURING THE UNIFORMITY OF CIVIL COURT PRACTICEhttps://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640aPharmaRadar360en2026-09-10T00:00:00.000ZLarval density, development, and distribution of Costelytra giveni in a first-year ryegrass–endophyte grazing trialhttps://www.pharmaradar360.com/article/the-contribution-of-instagram-influencers-to-drug-literacy-a-digital-communicati-9b940a97b351f178PharmaRadar360en2026-09-10T00:00:00.000ZThe Contribution of Instagram Influencers to Drug Literacy: A Digital Communication Perspectivehttps://www.pharmaradar360.com/article/one-year-comparison-of-three-maintenance-doses-of-vitamin-d3-600-1000-and-2000-i-7d271c298d361625PharmaRadar360en2026-09-10T00:00:00.000ZOne-Year Comparison of Three Maintenance Doses of Vitamin D₃ (600, 1000, and 2000 IU/day) on Metabolic Outcomes in Overweight and Obese Children: A Post-Hoc Analysis of a Randomized Trialhttps://www.pharmaradar360.com/article/drug-drug-interactions-and-pharmacological-complexity-as-prognostic-determinants-36411921172495c4PharmaRadar360en2026-09-10T00:00:00.000ZDrug–Drug Interactions and Pharmacological Complexity as Prognostic Determinants in Advanced Cholangiocarcinoma: A Real- World Study of the Drug-PIN® Scorehttps://www.pharmaradar360.com/article/when-thyrotropin-meets-growth-hormone-clinical-challenges-of-a-mixed-gh-tsh-secr-582838b0171f14b7PharmaRadar360en2026-09-10T00:00:00.000ZWhen Thyrotropin Meets Growth Hormone: Clinical Challenges of a Mixed GH/TSH-Secreting PIT1-Lineage Pituitary Neuroendocrine Tumorhttps://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9PharmaRadar360en2026-09-10T00:00:00.000ZIndications of a Dependent Invention for the Use of which a Compulsory License May be Granted in the Pharmaceutical Fieldhttps://www.pharmaradar360.com/article/integrating-clinical-and-cephalometric-assessment-a-comparative-review-b29ec57ce2d2f40aPharmaRadar360en2026-09-10T00:00:00.000ZIntegrating clinical and cephalometric assessment: a comparative reviewhttps://www.pharmaradar360.com/article/photodynamic-therapy-of-onychomycosis-modern-photosensitizers-and-clinical-effic-64ce2376748684d7PharmaRadar360en2026-09-10T00:00:00.000ZPhotodynamic therapy of onychomycosis: modern photosensitizers and clinical efficacy (literature review)https://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cdPharmaRadar360en2026-09-10T00:00:00.000ZProcedural and Clinical Outcomes of Second-generation Robotic-assisted versus Manual Percutaneous Coronary Intervention: A 1-year Follow-up Studyhttps://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2dPharmaRadar360en2026-09-10T00:00:00.000ZCardiac troponin in pediatric cardiology: toward standardized interpretive frameworks and clinical decision limitshttps://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5PharmaRadar360en2026-09-10T00:00:00.000ZA comparative evaluation of p-tau217 stability in serum and plasma using two validated assayshttps://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713ePharmaRadar360en2026-09-10T00:00:00.000ZDIN SPEC 91532: a process-oriented framework for quality assurance in clinical mass spectrometryhttps://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40PharmaRadar360en2026-09-10T00:00:00.000ZClinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatmenthttps://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358PharmaRadar360en2026-09-10T00:00:00.000ZClinical Impact of Hospital-Associated Disability in Patients With Acute Decompensated Heart Failurehttps://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209acaPharmaRadar360en2026-09-10T00:00:00.000ZHigh-Intensity Statins and the Post-Discharge Clinical Outcomes at 1 Year After Percutaneous Coronary Intervention ― Insights From STOPDAPT-3 ―https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67PharmaRadar360en2026-09-10T00:00:00.000ZEndomyocardial Biopsy and Clinical Outcomes in Acute Myocarditis ― Multicenter Cohort Study ―https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6PharmaRadar360en2026-09-10T00:00:00.000ZDetection of Crystalline Ibuprofen Components in Ibuprofen-Loaded SBA-15 Mesoporous Silica Using Time-Domain NMRhttps://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80PharmaRadar360en2026-09-10T00:00:00.000ZEvaluation of Water-Related &lt;i&gt;T&lt;/i&gt;&lt;sub&gt;2&lt;/sub&gt; Relaxation Behavior in Hot-Melt Extruded Clotrimazole/PVPVA Solid Dispersions Using Time-Domain NMRhttps://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977ePharmaRadar360en2026-09-10T00:00:00.000ZExploring the Therapeutic Impact of Targeting Brk in Epithelial-Derived Cancer Cellshttps://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235PharmaRadar360en2026-09-10T00:00:00.000ZRealgar Transforming Solution Triggers Ferroptosis-Associated Death in NB4 Leukemia Cells through Disruption of Iron Homeostasis and Suppression of the SLC7A11/GPX4 Axishttps://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7dPharmaRadar360en2026-09-10T00:00:00.000ZCritical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Prioritieshttps://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62PharmaRadar360en2026-09-10T00:00:00.000ZHydrophobic Compounds in the &lt;i&gt;Paeonia suffruticosa&lt;/i&gt; Root Cortex Reduce Lipid Accumulation in Adipocytes and the Livers of Obese &lt;i&gt;ob&lt;/i&gt;/&lt;i&gt;ob&lt;/i&gt; Micehttps://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773bPharmaRadar360en2026-09-10T00:00:00.000Z153ABR: Clinical Procedure Applicationshttps://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dbaPharmaRadar360en2026-09-10T00:00:00.000ZErratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertionshttps://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132PharmaRadar360en2026-09-10T00:00:00.000ZErratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trialshttps://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974PharmaRadar360en2026-09-10T00:00:00.000ZTherapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0PharmaRadar360en2026-09-10T00:00:00.000ZReply to: Role of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriershttps://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440baPharmaRadar360en2026-09-10T00:00:00.000ZReply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacyhttps://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724PharmaRadar360en2026-09-10T00:00:00.000ZIntismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Studyhttps://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0PharmaRadar360en2026-09-10T00:00:00.000ZHe Was Always Therehttps://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6PharmaRadar360en2026-09-10T00:00:00.000ZOlaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacyhttps://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcfPharmaRadar360en2026-09-10T00:00:00.000ZCOMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Advanced Melanomahttps://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60bPharmaRadar360en2026-09-10T00:00:00.000ZRole of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriershttps://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1fPharmaRadar360en2026-09-10T00:00:00.000ZDeveloping a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancerhttps://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faedPharmaRadar360en2026-09-10T00:00:00.000ZShould Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer?https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65PharmaRadar360en2026-09-10T00:00:00.000ZSustaining High Reliability Amid Artificial Intelligence Adoption in Oncologyhttps://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6fPharmaRadar360en2026-09-10T00:00:00.000ZOncology Drug Development: Challenges of Increasingly Available Therapieshttps://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbePharmaRadar360en2026-09-10T00:00:00.000ZImpact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Studyhttps://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0PharmaRadar360en2026-09-10T00:00:00.000ZDevelopment and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancerhttps://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaeaPharmaRadar360en2026-09-10T00:00:00.000ZPhase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239PharmaRadar360en2026-09-10T00:00:00.000ZMagrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Studyhttps://www.pharmaradar360.com/article/spotlighting-rising-researcher-lucas-attia-from-drug-nanoparticle-engineering-to-80d678c9fb2b6243PharmaRadar360en2026-09-10T00:00:00.000ZSpotlighting rising researcher Lucas Attia: from drug nanoparticle engineering to molecular property predictionhttps://www.pharmaradar360.com/article/comparative-changes-in-cardiovascular-measures-following-speed-agility-and-quick-7d38e12c591165cbPharmaRadar360en2026-09-10T00:00:00.000ZComparative changes in cardiovascular measures following speed, agility, and quickness training and small-sided games in youth football players: a randomized trialhttps://www.pharmaradar360.com/article/performance-of-artificial-intelligence-chatbots-in-restorative-dentistry-a-compa-9b191fa00532fd63PharmaRadar360en2026-09-10T00:00:00.000ZPerformance of artificial intelligence chatbots in restorative dentistry: a comparative analysis of clinical and theoretical specialty examination questionshttps://www.pharmaradar360.com/article/sterile-neutrophilic-pseudomembranous-conjunctivitis-associated-with-tisotumab-v-d38695f0b78e7a1bPharmaRadar360en2026-09-10T00:00:00.000ZSterile neutrophilic pseudomembranous conjunctivitis associated with tisotumab vedotin: clinical and cytological evidence from two caseshttps://www.pharmaradar360.com/article/comparison-of-two-tooth-whitening-treatments-a-randomized-split-mouth-clinical-t-c0c6e1e2d0ef8771PharmaRadar360en2026-09-10T00:00:00.000ZComparison of two tooth whitening treatments: a randomized split-mouth clinical trialhttps://www.pharmaradar360.com/article/clinical-observation-on-four-finger-pushing-manipulation-combined-with-acupunctu-a2814a38ddb8384aPharmaRadar360en2026-09-10T00:00:00.000ZClinical Observation on Four-Finger Pushing Manipulation Combined With Acupuncture in the Treatment of Cervical Vertigohttps://www.pharmaradar360.com/article/clinical-significance-of-inter-assay-discrepancies-and-regression-derived-correc-3228176469d0ff16PharmaRadar360en2026-09-10T00:00:00.000ZClinical significance of inter-assay discrepancies and regression-derived correction of serum CA19-9 values: a comparison between CLIA and ECLIAhttps://www.pharmaradar360.com/article/a-clinical-prediction-model-for-self-harm-after-adolescent-traumatic-brain-injur-e24ad5ae8d0cc3ddPharmaRadar360en2026-09-10T00:00:00.000ZA Clinical Prediction Model for Self-Harm After Adolescent Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/vancomycin-rescues-sensitivity-to-isoniazid-in-clinical-isolates-of-drug-resista-e8b7cbd1c4a03064PharmaRadar360en2026-09-10T00:00:00.000ZVancomycin rescues sensitivity to isoniazid in clinical isolates of drug-resistant <i>Mycobacterium tuberculosis</i>https://www.pharmaradar360.com/article/when-tests-don-t-fit-the-rules-regulatory-challenges-for-agnostic-metagenomic-ne-331f129d805b783bPharmaRadar360en2026-09-10T00:00:00.000ZWhen tests don’t fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnosticshttps://www.pharmaradar360.com/article/indications-techniques-and-complications-associated-with-pterygoid-implants-a-sy-83a100367b3cf247PharmaRadar360en2026-09-10T00:00:00.000ZIndications, Techniques and Complications Associated With Pterygoid Implants: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/diagnostic-yield-of-brain-mri-in-pediatric-short-stature-hypothalamic-pituitary-74fd0b47c4324c38PharmaRadar360en2026-09-10T00:00:00.000ZDiagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic–Pituitary Lesions and Incidental Findings in Real‐World Practicehttps://www.pharmaradar360.com/article/the-development-and-initial-validation-of-the-perinatal-intrusions-interpretatio-e0c5c555f7035197PharmaRadar360en2026-09-10T00:00:00.000ZThe development and initial validation of the Perinatal Intrusions Interpretation Index: A novel scale that measures negative appraisals of infant‐related intrusive thoughtshttps://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648PharmaRadar360en2026-09-10T00:00:00.000ZThe influence of social media on users’ intention to participate in clinical trials: a cross-country analysis using an adapted technology acceptance modelhttps://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942aPharmaRadar360en2026-09-10T00:00:00.000ZPrice gouging in the B2B pharmaceutical market: a systematic review of unethical pricing, market manipulation, and regulatory challengeshttps://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8ePharmaRadar360en2026-09-10T00:00:00.000ZHypnosis for Postoperative Pain Management Following Colectomies: A Single-Center Randomized Controlled Feasibility Trialhttps://www.pharmaradar360.com/article/heart-failure-among-people-with-hiv-prescription-of-guideline-directed-medical-t-13740b1e548b1bb9PharmaRadar360en2026-09-10T00:00:00.000ZHeart failure among people with HIV: prescription of guideline-directed medical therapyhttps://www.pharmaradar360.com/article/a-user-centric-patient-educational-intervention-in-clinical-practice-helping-wom-65d17fa745ccd8e6PharmaRadar360en2026-09-10T00:00:00.000ZA user-centric patient educational intervention in clinical practice: helping women to learn and share experiences about menopausehttps://www.pharmaradar360.com/article/autophagy-activation-in-granulosa-cells-as-a-mechanism-of-astaxanthin-action-evi-837d5d6cedcc31a1PharmaRadar360en2026-09-10T00:00:00.000ZAutophagy activation in granulosa cells as a mechanism of astaxanthin action: evidence from a pilot randomised trial in PMOS-associated infertilityhttps://www.pharmaradar360.com/article/silk-sericin-fibroin-composite-drug-delivery-systems-for-lung-cancer-mechanistic-8a8fa26cb15838c7PharmaRadar360en2026-09-10T00:00:00.000ZSilk sericin/fibroin composite drug delivery systems for lung cancer: mechanistic Rationale, potential functional complementarity, and future perspectiveshttps://www.pharmaradar360.com/article/effects-of-guided-imagery-supported-psychoeducation-on-self-esteem-perceived-str-081b38975cbead8ePharmaRadar360en2026-09-10T00:00:00.000ZEffects of Guided Imagery–Supported Psychoeducation on Self-Esteem, Perceived Stress, and Depressive Symptoms in Patients with Depression: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/applying-natural-language-processing-to-address-healthcare-bias-using-care-sd-to-ef4b247727690352PharmaRadar360en2026-09-10T00:00:00.000ZApplying Natural Language Processing to Address Healthcare Bias: Using CARE-SD to Evaluate the Distribution of Stigmatizing Language in Clinical Noteshttps://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9PharmaRadar360en2026-09-10T00:00:00.000ZWhen Fear Became the Barrier to Care — Lessons of a Clinical Rapid Response during Operation Metro Surgehttps://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83cPharmaRadar360en2026-09-10T00:00:00.000ZA Virtual Reality Cardiopulmonary Bypass Simulator Versus Conventional Halstedian Observation for Early Perfusion Education: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/how-lipid-ingestion-is-sensed-the-mechanisms-underlying-intestinal-hormone-secre-22afd06b3217a312PharmaRadar360en2026-09-10T00:00:00.000ZHow lipid ingestion is sensed: the mechanisms underlying intestinal hormone secretionhttps://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884PharmaRadar360en2026-09-10T00:00:00.000ZDifferential detection of tau aggregation species using a small molecule probe for cell-based drug screeninghttps://www.pharmaradar360.com/article/pre-treatment-prediction-of-ebv-dna-status-in-nasopharyngeal-carcinoma-using-ce-a68cbee4efda910cPharmaRadar360en2026-09-10T00:00:00.000ZPre-treatment prediction of EBV-DNA status in nasopharyngeal carcinoma using CE-T1WI radiomics combined with clinical features: a multi-sequence MRI radiomics studyhttps://www.pharmaradar360.com/article/integrating-artificial-intelligence-and-quantum-chemistry-for-sustainable-pharma-2d6f3ac18e807696PharmaRadar360en2026-09-10T00:00:00.000ZIntegrating artificial intelligence and quantum chemistry for sustainable pharmaceutical retrosynthesishttps://www.pharmaradar360.com/article/author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual-care-55d47fa59cf1d06dPharmaRadar360en2026-09-10T00:00:00.000ZAuthor Correction: Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trialhttps://www.pharmaradar360.com/article/aptamer-functionalized-dna-frameworks-as-targeted-drug-buffers-for-concentration-80b9dd9403406b46PharmaRadar360en2026-09-10T00:00:00.000ZAptamer-Functionalized DNA Frameworks as Targeted Drug Buffers for Concentration Regulation of Maytansinehttps://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5PharmaRadar360en2026-09-10T00:00:00.000ZAn explainable AI framework for early mental health screening and clinical decision support using reflective listening and generative AIhttps://www.pharmaradar360.com/article/trust-and-the-reliability-of-ai-algorithms-for-clinical-decision-making-support-9e4b561742c5eac6PharmaRadar360en2026-09-10T00:00:00.000ZTrust and the reliability of AI algorithms for clinical decision-making support in medicine: the MIRACLE case studyhttps://www.pharmaradar360.com/article/potenzial-und-herausforderungen-von-large-language-models-in-der-klinischen-ents-aab5af7bbb512e77PharmaRadar360en2026-09-10T00:00:00.000ZPotenzial und Herausforderungen von Large Language Models in der klinischen Entscheidungsfindunghttps://www.pharmaradar360.com/article/the-deubiquitinating-enzyme-regulatory-network-in-malignant-progression-of-breas-1ae6f24cf43a9983PharmaRadar360en2026-09-10T00:00:00.000ZThe deubiquitinating enzyme regulatory network in malignant progression of breast cancer encompasses mechanisms of action, clinical significance and emerging therapeutic targetshttps://www.pharmaradar360.com/article/clinical-laboratory-and-radiological-factors-associated-with-posterior-reversibl-ada55e4fd84835f5PharmaRadar360en2026-09-10T00:00:00.000ZClinical, Laboratory and Radiological Factors associated with posterior reversible encephalopathy syndrome (PRES) in patients with eclampsia or pre-eclampsia: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/agreement-between-artificial-intelligence-and-periodontists-in-the-detection-of-19457d539500c908PharmaRadar360en2026-09-10T00:00:00.000ZAgreement between artificial intelligence and periodontists in the detection of periodontal bone loss on panoramic radiographshttps://www.pharmaradar360.com/article/preserving-beta-cell-function-in-children-and-adolescents-with-newly-diagnosed-s-57b94481282b6072PharmaRadar360en2026-09-10T00:00:00.000ZPreserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trialhttps://www.pharmaradar360.com/article/nct07813208-ph-all-in-chinese-children-diagnosis-treatment-and-survival-eb09a4a0ca15599dPharmaRadar360en2026-09-10T00:00:00.000ZNCT07813208: Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survivalhttps://www.pharmaradar360.com/article/nct07812636-tirzepatide-and-levonorgestrel-iud-therapy-for-ein-and-early-stage-e-62fa618027a35796PharmaRadar360en2026-09-10T00:00:00.000ZNCT07812636: Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancerhttps://www.pharmaradar360.com/article/nct07812402-the-effect-of-factors-affecting-bone-mineral-density-measurement-res-2973f03482cf3684PharmaRadar360en2026-09-10T00:00:00.000ZNCT07812402: The Effect of Factors Affecting Bone Mineral Density Measurement Results on Osteoporosis Diagnosis and Treatment Decisionhttps://www.pharmaradar360.com/article/nct07812142-retrospective-analysis-of-the-second-year-of-safety-surveillance-of-2d8c760820377312PharmaRadar360en2026-09-10T00:00:00.000ZNCT07812142: Retrospective Analysis of the Second Year of Safety Surveillance of the Qdenga® (TAK-003) Vaccine in Private Vaccination Centers, Including a Sub-analysis of Safety in Adults Over 60 Years of Agehttps://www.pharmaradar360.com/article/nct07811817-the-outcomes-of-sympathetic-cardiac-denervation-on-postoperative-atr-6898ffb279287097PharmaRadar360en2026-09-10T00:00:00.000ZNCT07811817: The Outcomes of Sympathetic Cardiac Denervation on Postoperative Atrial Fibrillation After Cardiac Surgery, Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07807579-impact-of-dexmedetomidine-versus-propofol-on-intracranial-pressure-i-3ebfbb09eb810a2cPharmaRadar360en2026-09-10T00:00:00.000ZNCT07807579: Impact of Dexmedetomidine Versus Propofol on Intracranial Pressure in Adult Traumatic Brain Injury Patients: Randomized Controlled Double-Blind Trialhttps://www.pharmaradar360.com/article/nct07802639-treatment-for-asymmetric-crying-facies-6a5482072b6db189PharmaRadar360en2026-09-10T00:00:00.000ZNCT07802639: Treatment for "Asymmetric Crying Facies"https://www.pharmaradar360.com/article/nct07796880-neoadjuvant-culmerciclib-combined-with-endocrine-therapy-for-hormone-236a6ff0dd7aaab3PharmaRadar360en2026-09-10T00:00:00.000ZNCT07796880: Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer